Subcutaneous Epcoritamab Brings 82% Overall Response in Patients With R/R Follicular Lymphoma

Epcoritamab, sold as Epkinly, is already approved to treat certain types of large B-cell lymphoma. This article will appear in the January 2024 issue of Evidence-Based Oncology.™

Related Keywords

Paris ,France General ,France ,California ,United States ,San Diego ,American ,Catherine Thieblemont ,Mosunetuzumab Lunsumio ,Phd Paris University ,Paris University ,American Society Of Hematology Annual Meeting ,American Society Of Hematology ,Genentech ,American Society ,Annual Meeting ,Breakthrough Therapy Designation ,Through October ,Saint Louis Assistance Publique H ,Hematology Annual Meeting ,Dlbcbl ,Follicular Lymphoma ,Epcoritamab ,Tepkinly ,Genmab ,